Tag: polymyalgia rheumatica market drivers

Uncover key drivers, emerging technologies, and competitive movements shaping the polymyalgia rheumatica market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Polymyalgia Rheumatica Market in 2030?

The market for polymyalgia rheumatica has shown robust expansion over the past few years. Projections indicate it will expand from $1.36 billion in 2025 to reach $1.44 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 6.2%. Historically, this expansion has been driven by factors such as a rising elderly demographic, enhanced clinical understanding of inflammatory conditions, the widespread adoption of corticosteroids as the initial treatment, increasing diagnostic rates among older patients, and the provision of rheumatology care within hospitals.

The polymyalgia rheumatica market size is projected to observe significant expansion in the coming years. It is forecast to grow to $1.81 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.9%. This anticipated growth during the forecast period is largely due to the increasing development of steroid-sparing therapies, escalating research into inflammatory biomarkers, the rising adoption of biologics and targeted drugs, expanding access to specialized medical care, and a growing focus on reducing long-term treatment side effects. Prominent trends expected in this period include the increased uptake of biologic therapies, a heightened focus on early and accurate diagnosis, the growing implementation of long-term corticosteroid management, the expansion of personalized treatment approaches, and enhanced monitoring of disease progression.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22103&type=smp

What Drivers Are Influencing Production Trends In The Polymyalgia Rheumatica Market?

The increasing demand for personalized medicine is anticipated to propel the expansion of the polymyalgia rheumatica market moving forward. Personalized medicine refers to medical care specifically adapted to an individual’s genetic profile, lifestyle, and unique health conditions to achieve more effective results. The impetus behind the need for personalized medicine stems from breakthroughs in genetic research, rising patient desires for customized therapies, and enhancements in diagnostic technologies. Genetic research has provided a profound understanding of distinct genetic variations, enabling the creation of more tailored treatments aimed at specific genetic markers. This approach helps in selecting drugs most likely to be effective based on the patient’s characteristics, thereby leading to a more efficient and secure treatment strategy. For instance, in February 2024, according to the Personalised Medicine Coalition, a US-based hospital and health care organization, in 2023, the Food and Drug Administration approved 16 new personalized treatments for rare disease patients, which was an increase from six in 2022. Consequently, the advent of personalized medicine is fueling the growth of the polymyalgia rheumatica market.

Which Segments Are Gaining Traction In The Polymyalgia Rheumatica Market?

The polymyalgia rheumatica market covered in this report is segmented –

1) By Treatment: Corticosteroids, Nonsteroidal Anti-Inflammatory Drugs, Disease-Modifying Antirheumatic Drugs, Biologics

2) By Route Of Administration: Oral, Intravenous, Subcutaneous

3) By Patient Type: Adult, Geriatric, Elderly Or Aging Population

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Corticosteroids: Prednisone, Methylprednisolone, Hydrocortisone, Dexamethasone

2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Naproxen, Aspirin, Celecoxib

3) By Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine

4) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin-6 (IL-6) Inhibitors, B-Cell Inhibitors, Janus Kinase (JAK) Inhibitors

Which Trends Are Shaping Activity Within The Polymyalgia Rheumatica Market?

Leading firms within the polymyalgia rheumatica market are prioritizing the creation of advanced medications, including interleukin-6 (IL-6) receptor blockers, to offer more precise and potent therapeutic alternatives. These interleukin-6 (IL-6) receptor blockers function as biological agents, working to suppress IL-6, a significant pro-inflammatory cytokine implicated in autoimmune conditions. Their mechanism of action, by inhibiting IL-6, leads to a reduction in inflammation and an alleviation of symptoms, thereby improving the quality of life for individuals suffering from PMR. As an illustration, in February 2023, Regeneron Pharmaceuticals, Inc., a US-based biotechnology firm, together with Sanofi, a France-based healthcare enterprise, disclosed that the Food and Drug Administration (FDA) had granted approval for Kevzara (sarilumab) to treat polymyalgia rheumatica (PMR) in adults who had not adequately responded to corticosteroids or were unable to gradually discontinue their use. Kevzara, notably the inaugural and sole biologic medication sanctioned for this ailment, operates by preventing IL-6-mediated signaling pathways. This approval stemmed from a clinical investigation demonstrating that 28.3% of patients receiving sarilumab attained sustained remission by week 52, in contrast to 10.3% of those on placebo. Kevzara is administered through subcutaneous injection bi-weekly and has also secured approval for the management of moderately to severely active rheumatoid arthritis. Currently, Sanofi’s stock (SNY) trades at $54.13 on the NASDAQ.

Who Are The Major Companies Operating In The Polymyalgia Rheumatica Market?

Major companies operating in the polymyalgia rheumatica market are AbbVie Inc., Sanofi S.A., Eli Lilly and Co., Regeneron Pharmaceuticals Inc., Horizon Therapeutics plc, Sparrow Pharmaceuticals Inc., Roche Holding AG, Novartis AG, Pfizer Inc., Bristol Myers Squibb Company, GlaxoSmithKline plc, AstraZeneca plc, Merck & Co. Inc., Janssen Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, UCB S.A., Amgen Inc., Boehringer Ingelheim, Bayer AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Lupin Limited, Aurobindo Pharma Limited

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/polymyalgia-rheumatica-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Polymyalgia Rheumatica Market?

Asia-Pacific was the largest region in the polymyalgia rheumatica market in 2025. The regions covered in the polymyalgia rheumatica market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Polymyalgia Rheumatica Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22103&type=smp

Browse Through More Reports Similar to the Global Polymyalgia Rheumatica Market 2026, By The Business Research Company

Sciatica Market Report 2026

https://www.thebusinessresearchcompany.com/report/sciatica-global-market-report

Fibromyalgia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/fibromyalgia-treatment-global-market-report

Esophageal Dysphagia Market Report 2026

https://www.thebusinessresearchcompany.com/report/esophageal-dysphagia-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the polymyalgia rheumatica market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Polymyalgia Rheumatica Market in 2030?

The market for polymyalgia rheumatica has shown robust expansion over the past few years. Projections indicate it will expand from $1.36 billion in 2025 to reach $1.44 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 6.2%. Historically, this expansion has been driven by factors such as a rising elderly demographic, enhanced clinical understanding of inflammatory conditions, the widespread adoption of corticosteroids as the initial treatment, increasing diagnostic rates among older patients, and the provision of rheumatology care within hospitals.

The polymyalgia rheumatica market size is projected to observe significant expansion in the coming years. It is forecast to grow to $1.81 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.9%. This anticipated growth during the forecast period is largely due to the increasing development of steroid-sparing therapies, escalating research into inflammatory biomarkers, the rising adoption of biologics and targeted drugs, expanding access to specialized medical care, and a growing focus on reducing long-term treatment side effects. Prominent trends expected in this period include the increased uptake of biologic therapies, a heightened focus on early and accurate diagnosis, the growing implementation of long-term corticosteroid management, the expansion of personalized treatment approaches, and enhanced monitoring of disease progression.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22103&type=smp

What Drivers Are Influencing Production Trends In The Polymyalgia Rheumatica Market?

The increasing demand for personalized medicine is anticipated to propel the expansion of the polymyalgia rheumatica market moving forward. Personalized medicine refers to medical care specifically adapted to an individual’s genetic profile, lifestyle, and unique health conditions to achieve more effective results. The impetus behind the need for personalized medicine stems from breakthroughs in genetic research, rising patient desires for customized therapies, and enhancements in diagnostic technologies. Genetic research has provided a profound understanding of distinct genetic variations, enabling the creation of more tailored treatments aimed at specific genetic markers. This approach helps in selecting drugs most likely to be effective based on the patient’s characteristics, thereby leading to a more efficient and secure treatment strategy. For instance, in February 2024, according to the Personalised Medicine Coalition, a US-based hospital and health care organization, in 2023, the Food and Drug Administration approved 16 new personalized treatments for rare disease patients, which was an increase from six in 2022. Consequently, the advent of personalized medicine is fueling the growth of the polymyalgia rheumatica market.

Which Segments Are Gaining Traction In The Polymyalgia Rheumatica Market?

The polymyalgia rheumatica market covered in this report is segmented –

1) By Treatment: Corticosteroids, Nonsteroidal Anti-Inflammatory Drugs, Disease-Modifying Antirheumatic Drugs, Biologics

2) By Route Of Administration: Oral, Intravenous, Subcutaneous

3) By Patient Type: Adult, Geriatric, Elderly Or Aging Population

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Corticosteroids: Prednisone, Methylprednisolone, Hydrocortisone, Dexamethasone

2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Naproxen, Aspirin, Celecoxib

3) By Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine

4) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin-6 (IL-6) Inhibitors, B-Cell Inhibitors, Janus Kinase (JAK) Inhibitors

Which Trends Are Shaping Activity Within The Polymyalgia Rheumatica Market?

Leading firms within the polymyalgia rheumatica market are prioritizing the creation of advanced medications, including interleukin-6 (IL-6) receptor blockers, to offer more precise and potent therapeutic alternatives. These interleukin-6 (IL-6) receptor blockers function as biological agents, working to suppress IL-6, a significant pro-inflammatory cytokine implicated in autoimmune conditions. Their mechanism of action, by inhibiting IL-6, leads to a reduction in inflammation and an alleviation of symptoms, thereby improving the quality of life for individuals suffering from PMR. As an illustration, in February 2023, Regeneron Pharmaceuticals, Inc., a US-based biotechnology firm, together with Sanofi, a France-based healthcare enterprise, disclosed that the Food and Drug Administration (FDA) had granted approval for Kevzara (sarilumab) to treat polymyalgia rheumatica (PMR) in adults who had not adequately responded to corticosteroids or were unable to gradually discontinue their use. Kevzara, notably the inaugural and sole biologic medication sanctioned for this ailment, operates by preventing IL-6-mediated signaling pathways. This approval stemmed from a clinical investigation demonstrating that 28.3% of patients receiving sarilumab attained sustained remission by week 52, in contrast to 10.3% of those on placebo. Kevzara is administered through subcutaneous injection bi-weekly and has also secured approval for the management of moderately to severely active rheumatoid arthritis. Currently, Sanofi’s stock (SNY) trades at $54.13 on the NASDAQ.

Who Are The Major Companies Operating In The Polymyalgia Rheumatica Market?

Major companies operating in the polymyalgia rheumatica market are AbbVie Inc., Sanofi S.A., Eli Lilly and Co., Regeneron Pharmaceuticals Inc., Horizon Therapeutics plc, Sparrow Pharmaceuticals Inc., Roche Holding AG, Novartis AG, Pfizer Inc., Bristol Myers Squibb Company, GlaxoSmithKline plc, AstraZeneca plc, Merck & Co. Inc., Janssen Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, UCB S.A., Amgen Inc., Boehringer Ingelheim, Bayer AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Lupin Limited, Aurobindo Pharma Limited

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/polymyalgia-rheumatica-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Polymyalgia Rheumatica Market?

Asia-Pacific was the largest region in the polymyalgia rheumatica market in 2025. The regions covered in the polymyalgia rheumatica market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Polymyalgia Rheumatica Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22103&type=smp

Browse Through More Reports Similar to the Global Polymyalgia Rheumatica Market 2026, By The Business Research Company

Sciatica Market Report 2026

https://www.thebusinessresearchcompany.com/report/sciatica-global-market-report

Fibromyalgia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/fibromyalgia-treatment-global-market-report

Esophageal Dysphagia Market Report 2026

https://www.thebusinessresearchcompany.com/report/esophageal-dysphagia-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Present And Forecasted Size Of The Polymyalgia Rheumatica Market?

Over the recent years, there has been a notable surge in the market size of polymyalgia rheumatica. The market is projected to expand from $1.28 billion in the year 2024 to $1.36 billion in 2025, registering a compound annual growth rate (CAGR) of 5.9%. The historic growth is credited to heightened awareness among healthcare professionals, increased usage of corticosteroids, expansion of specialty clinics, the introduction of biologic therapies, and escalation in healthcare budgets.

The market for polymyalgia rheumatica is predicted to experience significant growth in the upcoming years, reaching a value of $1.72 billion by 2029 with a 6.1% compound annual growth rate (CAGR). This growth during the forecast period can be accredited to the increased use of biologics, the rise of precision medicine, swift drug approvals, comprehensive reimbursements, and the widening of clinical trials. Key trends for the forecast period encompass the development of combined therapies, progress in personalized medicine, the advancement of precision medicine, the incorporation of electronic health records, and the development in biomarkers.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22103&type=smp

What Underlying Factors Are Supporting The Polymyalgia Rheumatica Market Growth?

The growth of the polymyalgia rheumatica market is expected to be fueled by an increasing demand for personalized medicine. This form of medical treatment is custom-made according to each individual’s genetic makeup, lifestyle, and specific health conditions, and it tends to yield more effective outcomes. What’s driving this demand is progress in genetic research, rising expectations from patients for treatment specifically designed for them, and better diagnostic technologies. Genetic research has deepened our understanding of individual genetic differences, enabling more tailored treatments that target specific genetic markers. By selecting drugs that are the most likely to be effective based on a patient’s unique traits, personalized medicine offers a treatment plan that is safer and more effective. For example, the Personalised Medicine Coalition reports that in February 2024, a US-based hospital and healthcare organization revealed that the Food and Drug Administration approved 16 new personalized treatments for patients with rare diseases in 2023, a significant rise from six new approvals in 2022. Thus, the rise in personalized medicine is propelling the growth of the polymyalgia rheumatica market.

How Does The Polymyalgia Rheumatica Market Differ By Segment?

The polymyalgia rheumaticamarket covered in this report is segmented –

1) By Treatment: Corticosteroids; Nonsteroidal Anti-Inflammatory Drugs; Disease-Modifying Antirheumatic Drugs; Biologics

2) By Route Of Administration: Oral; Intravenous; Subcutaneous

3) By Patient Type: Adult; Geriatric; Periatric

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Subsegments:

1) By Corticosteroids: Prednisone; Methylprednisolone; Hydrocortisone; Dexamethasone

2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen; Naproxen; Aspirin; Celecoxib

3) By Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate; Leflunomide; Sulfasalazine; Hydroxychloroquine

4) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors; Interleukin-6 (IL-6) Inhibitors; B-Cell Inhibitors; Janus Kinase (JAK) Inhibitors

What Are The Dominant Trends Currently Seen In The Polymyalgia Rheumatica Market?

Leading firms in the polymyalgia rheumatica market are focusing on interleukin-6 (IL-6) receptor blockers for targeted, effective treatments. These biologics inhibit IL-6, a key inflammatory cytokine in autoimmune diseases, reducing symptoms and improving patient quality of life. For instance, in February 2023, Regeneron Pharmaceuticals (US) and Sanofi (France) announced FDA approval of Kevzara (sarilumab) for adults with polymyalgia rheumatica who do not respond well to corticosteroids. Kevzara, the first biologic approved for this condition, blocks IL-6 signaling and showed significant remission rates in clinical trials. Administered via biweekly subcutaneous injection, Kevzara is also approved for rheumatoid arthritis.

Who Are The Global Leaders Steering The Polymyalgia Rheumatica Market Forward?

Major companies operating in the polymyalgia rheumatica market are AbbVie Inc., Sanofi S.A., Eli Lilly and Co., Regeneron Pharmaceuticals Inc., Mount Sinai, NYU Langone Health, Mayo Foundation for Medical Education and Research, Hartford HealthCare, Horizon Therapeutics plc, Massachusetts General Hospital, Brigham and Women’s Hospital, Stanford Health Care, University Hospitals Bristol NHS Foundation Trust, Circle Health Group Ltd., Siloam Hospital, UC San Diego Health, Vejthani Hospital, Sparrow Pharmaceuticals Inc., Johns Hopkins Arthritis Center, Upstate University Hospital

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/polymyalgia-rheumatica-global-market-report

Which Region Is Likely To Register The Fastest Growth In The Polymyalgia Rheumatica Market?

Asia-Pacific was the largest region in the polymyalgia rheumatica market in 2024. The regions covered in the polymyalgia rheumatica market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=22103&type=smp

Browse Through More Reports Similar to the Global Polymyalgia Rheumatica Market 2025, By The Business Research Company

Bipolar Disorder Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bipolar-disorder-therapeutics-global-market-report

Hpv Associated Disorders Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hpv-associated-disorders-global-market-report

Bleeding Disorders Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bleeding-disorders-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Big Is The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Today And What Is Its Future Size?

In recent times, there has been a rapid expansion in the poly (adp-ribose) polymerase (parp) inhibitors market. The market size is anticipated to rise from $6.53 billion in 2024 to $7.49 billion in 2025, displaying a compound annual growth rate (CAGR) of 14.8%. Factors contributing to this growth over the historical period include an increase in cancer cases, a rise in genetic testing, successful clinical trials, expanding insurance coverage, and advancements in cancer research.

The poly (adp-ribose) polymerase (parp) inhibitors market is anticipated to experience swift expansion in the upcoming years, projecting to reach a worth of $13.15 billion by 2029, with a compound annual growth rate (CAGR) of 15.1%. Factors contributing to this growth over the predicted period include increasing production and distribution of medications, escalating cases of BRCA-mutated cancers, a surge in breast cancer prevalence, enhanced usage of monoclonal antibodies, and augmented healthcare spending. The forecast period also identifies key trends such as improvements in biomarker studies, implementation of combination therapies, application of artificial intelligence in pharmaceutical advancements, progress in biomarker-oriented treatment, and the evolution of next-generation PARP inhibitors.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22102&type=smp

Which Demand Drivers Are Strengthening The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market?

The increasing incidence of breast cancer is anticipated to stimulate the expansion of the poly(ADP-ribose) polymerase (PARP) inhibitors market. Breast cancer is a condition characterized by the uncontrolled proliferation of cells in the breast, forming a harmful tumor with the potential to metastasize to other bodily parts. Factors contributing to the escalating incidence of breast cancer include an aging population, alterations in lifestyle, genetic susceptibility, hormonal imbalances, obesity, alcohol intake, and growing exposure to environmental hazards. PARP inhibitors aid breast cancer sufferers by inhibiting the PARP enzyme’s DNA repair function in cancerous cells, resulting in cell death, especially in tumors with BRCA1 or BRCA2 mutations. For example, data from the US-based National Breast Cancer Foundation in January 2025, indicates that one out of every eight women in the United States will be diagnosed with breast cancer in her lifetime. In 2024, diagnoses for invasive breast cancer were given to 310,720 women and 2,800 men. Hence, the escalating incidence of breast cancer is fueling the growth of the poly(ADP-ribose) polymerase (PARP) inhibitors market.

Which Segment Accounts For The Largest Share In The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market?

The poly (adp-ribose) polymerase (parp) inhibitorsmarket covered in this report is segmented –

1) By Type: Olaparib; Rucaparib; Niraparib; Talazoparib; Other Types

2) By Indication: Ovarian Cancer; Breast Cancer; Prostate Cancer; Pancreatic Cancer

3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

4) By End-User: Hospitals; Specialty Clinics; Research Institutions; Other End-Users

Subsegments:

1) By Olaparib: BRCA-Mutated Cancers; HRD-Positive Cancers; Maintenance Therapy

2) By Rucaparib: Ovarian Cancer; Prostate Cancer; Pancreatic Cancer

3) By Niraparib: First-Line Treatment; Recurrent Cancer Treatment; Late-Stage Cancer

4) By Talazoparib: Breast Cancer; Germline BRCA-Mutated Tumors; Neoadjuvant Or Adjuvant Therapy

5) By Other Types: Emerging PARP Inhibitors; Investigational Therapies; Novel Combinations

Which Disruptive Trends Are Driving Change Across The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market?

Key players in the poly(ADP-ribose) polymerase (PARP) inhibitors market are developing targeted anticancer drugs aimed at genetic mutations found in specific cancers. These drugs work by inhibiting cancer cell growth, preventing spread, or activating immune response. For example, in March 2024, Zydus Lifesciences Limited, an Indian pharmaceutical company, launched IBYRA, a generic PARP inhibitor olaparib, providing an affordable treatment for HRD-positive and BRCA-positive cancers, significantly reducing costs compared to the original drug.

Which Companies Hold A Competitive Edge In The 1583 Market?

Major companies operating in the poly(ADP-ribose) polymerase (PARP) inhibitors market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Merck & Co. Inc., Bayer AG, AstraZeneca plc, Bristol-Myers Squibb Company, GSK plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim, Vertex Pharmaceuticals Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., BeiGene LTD, Karyopharm Therapeutics Inc., Clovis Oncology Inc., Repare Therapeutics Inc., Ribon Therapeutics, Artios Pharma, IMPACT Therapeutics Inc., BiPar Sciences Inc., Allarity Therapeutics Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/polyadp-ribose-polymerase-parp-inhibitors-global-market-report

Which Region Is Forecasted To Lead The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market In The Coming Years?

North America was the largest region in the poly(ADP-ribose) polymerase (PARP) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the poly(ADP-ribose) polymerase (PARP) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=22102&type=smp

Browse Through More Reports Similar to the Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market 2025, By The Business Research Company

Her2 Inhibitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/her2-inhibitor-global-market-report

Checkpoint Inhibitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-global-market-report

Protein Inhibitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/protein-inhibitor-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Market Value Is The Polymyalgia Rheumatica Industry Expected To Reach By 2029, Starting From 2025 Levels?

The market for polymyalgia rheumatica has experienced substantial growth in recent years. It is anticipated to increase from $1.28 billion in 2024 to $1.36 billion in 2025, achieving a compound annual growth rate (CAGR) of 5.9%. This historical growth can be attributed to heightened awareness among healthcare providers, the increasing adoption of corticosteroids, the expansion of specialty clinics, the introduction of biologic therapies, and rising healthcare budgets.

The polymyalgia rheumatica market is projected to experience significant expansion over the next few years, with its size anticipated to reach $1.72 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.1%. This growth during the forecast period is primarily fueled by increasing adoption of biologics, the expanding field of precision medicine, accelerated drug approvals, broader reimbursement policies, and an increase in clinical trials. Furthermore, major trends anticipated in this period include the development of combination therapies, advancements in personalized medicine, continued evolution of precision medicine, the integration of electronic health records, and breakthroughs in biomarkers.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22103&type=smp

Which Drivers Are Supporting Growth Of The Polymyalgia Rheumatica Market?

The expanding need for personalized medicine is anticipated to drive the future expansion of the polymyalgia rheumatica market. This approach involves medical care customized to an individual’s unique genetic makeup, way of life, and particular health status, aiming for superior results. The impetus for personalized medicine stems from progress in genetic studies, increasing patient desires for customized therapies, and enhancements in diagnostic tools. Genetic research has deepened our comprehension of individual genetic differences, facilitating more bespoke treatments that target particular genetic markers. It aids in choosing medications most likely to be effective given a patient’s traits, resulting in a safer and more impactful treatment strategy. As an illustration, in February 2024, data from the Personalised Medicine Coalition, a US-based hospital and health care entity, revealed that in 2023, the Food and Drug Administration cleared 16 new personalized therapies for rare disease patients, an increase from six in 2022. Consequently, the emergence of personalized medicine is a key factor propelling the expansion of the polymyalgia rheumatica market.

What Are The Leading Segments Analyzed In The Polymyalgia Rheumatica Market?

The polymyalgia rheumaticamarket covered in this report is segmented –

1) By Treatment: Corticosteroids; Nonsteroidal Anti-Inflammatory Drugs; Disease-Modifying Antirheumatic Drugs; Biologics

2) By Route Of Administration: Oral; Intravenous; Subcutaneous

3) By Patient Type: Adult; Geriatric; Periatric

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Subsegments:

1) By Corticosteroids: Prednisone; Methylprednisolone; Hydrocortisone; Dexamethasone

2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen; Naproxen; Aspirin; Celecoxib

3) By Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate; Leflunomide; Sulfasalazine; Hydroxychloroquine

4) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors; Interleukin-6 (IL-6) Inhibitors; B-Cell Inhibitors; Janus Kinase (JAK) Inhibitors

What Long-Term Trends Will Shape The Future Growth Of The Polymyalgia Rheumatica Industry?

Companies prominent in the polymyalgia rheumatica market are prioritizing the development of advanced medications, such as interleukin-6 (IL-6) receptor blockers, to offer more targeted and effective treatment options. Interleukin-6 (IL-6) receptor blockers are biological drugs that work by inhibiting IL-6, a key pro-inflammatory cytokine in autoimmune diseases. By blocking IL-6, these therapies reduce inflammation and alleviate symptoms, thereby improving the quality of life for PMR patients. As an illustration, in February 2023, Regeneron Pharmaceuticals, Inc., a US-based biotechnology company, and Sanofi, a France-based healthcare company, announced that the Food and Drug Administration (FDA) had approved Kevzara (sarilumab) for treating polymyalgia rheumatica (PMR) in adults who either did not respond adequately to corticosteroids or could not tolerate their tapering. Kevzara, which is the first and only biologic approved for this condition, operates by inhibiting IL-6-mediated signaling. This approval was granted based on a study where 28.3% of patients on sarilumab achieved sustained remission at week 52, compared to 10.3% of those on placebo. Kevzara is administered via subcutaneous injection once every two weeks and is also approved for treating moderately to severely active rheumatoid arthritis. Sanofi’s stock (SNY) is currently valued at $54.13 on the NASDAQ.

Which Leading Companies Dominate The Polymyalgia Rheumatica Market Share?

Major companies operating in the polymyalgia rheumatica market are AbbVie Inc., Sanofi S.A., Eli Lilly and Co., Regeneron Pharmaceuticals Inc., Mount Sinai, NYU Langone Health, Mayo Foundation for Medical Education and Research, Hartford HealthCare, Horizon Therapeutics plc, Massachusetts General Hospital, Brigham and Women’s Hospital, Stanford Health Care, University Hospitals Bristol NHS Foundation Trust, Circle Health Group Ltd., Siloam Hospital, UC San Diego Health, Vejthani Hospital, Sparrow Pharmaceuticals Inc., Johns Hopkins Arthritis Center, Upstate University Hospital

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/polymyalgia-rheumatica-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Polymyalgia Rheumatica Market?

Asia-Pacific was the largest region in the polymyalgia rheumatica market in 2024. The regions covered in the polymyalgia rheumatica market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Polymyalgia Rheumatica Market Report:

https://www.thebusinessresearchcompany.com/customise?id=22103&type=smp

Browse Through More Reports Similar to the Global Polymyalgia Rheumatica Market 2025, By The Business Research Company

Bipolar Disorder Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bipolar-disorder-therapeutics-global-market-report

Hpv Associated Disorders Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hpv-associated-disorders-global-market-report

Bleeding Disorders Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bleeding-disorders-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Anticipated Size Of The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Over The Five-Year Period 2025–2029?

The poly (adp-ribose) polymerase (parp) inhibitors market has experienced swift expansion recently. Forecasts indicate it will expand from $6.53 billion in 2024 to $7.49 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 14.8%. This historical growth is linked to factors such as a rise in cancer cases, expanded genetic testing, greater success in clinical trials, broader insurance coverage, and enhanced cancer research efforts.

The poly (adp-ribose) polymerase (parp) inhibitors market is poised for significant expansion in the coming years. Projections indicate its size will reach $13.15 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 15.1%. This anticipated growth during the forecast period is primarily driven by factors such as increased drug production and supply, the escalating incidence of BRCA-mutated cancers, the rising prevalence of breast cancer, the expanded application of monoclonal antibodies, and increasing healthcare spending. Key trends influencing this market include progress in biomarker research, the emergence of combination therapies, the incorporation of artificial intelligence into drug development processes, strides in biomarker-driven therapy, and the creation of next-generation PARP inhibitors.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22102&type=smp

Which Drivers Are Shaping The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Industry’s Market Share?

The increasing incidence of breast cancer is anticipated to drive the expansion of the poly(ADP-ribose) polymerase (PARP) inhibitors market in the future. Breast cancer is defined as a condition where breast cells multiply without control, creating a malignant tumor capable of metastasizing to other bodily regions. This growing prevalence stems from factors including an aging global population, shifts in lifestyle, genetic susceptibilities, hormonal disruptions, obesity, alcohol intake, and heightened exposure to environmental hazards. PARP inhibitors offer therapeutic benefits to breast cancer patients by obstructing the PARP enzyme’s capacity to mend DNA damage within cancer cells, thereby inducing cell demise, especially in tumors possessing BRCA1 or BRCA2 mutations. For example, the National Breast Cancer Foundation, a US-based entity, reported in January 2025 that one in every eight women in the United States is projected to receive a breast cancer diagnosis at some point in her life. During 2024, 310,720 women and 2,800 men were diagnosed with invasive forms of breast cancer. Consequently, the increasing incidence of breast cancer is a key driver for the expansion of the poly(ADP-ribose) polymerase (PARP) inhibitors market.

What Are The Segment Types Shaping The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market?

The poly (adp-ribose) polymerase (parp) inhibitorsmarket covered in this report is segmented –

1) By Type: Olaparib; Rucaparib; Niraparib; Talazoparib; Other Types

2) By Indication: Ovarian Cancer; Breast Cancer; Prostate Cancer; Pancreatic Cancer

3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

4) By End-User: Hospitals; Specialty Clinics; Research Institutions; Other End-Users

Subsegments:

1) By Olaparib: BRCA-Mutated Cancers; HRD-Positive Cancers; Maintenance Therapy

2) By Rucaparib: Ovarian Cancer; Prostate Cancer; Pancreatic Cancer

3) By Niraparib: First-Line Treatment; Recurrent Cancer Treatment; Late-Stage Cancer

4) By Talazoparib: Breast Cancer; Germline BRCA-Mutated Tumors; Neoadjuvant Or Adjuvant Therapy

5) By Other Types: Emerging PARP Inhibitors; Investigational Therapies; Novel Combinations

Which Market Trends Are Creating New Opportunities In The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Industry?

Major companies operating in the poly(ADP-ribose) polymerase (PARP) inhibitors market are concentrating on developing advanced cancer treatments, specifically anticancer medicines, to target particular genetic mutations found in certain cancers. These medicines are utilized to combat cancer by either inhibiting the growth of cancer cells, preventing their spread, or destroying them, working through diverse mechanisms such as interfering with cell division, blocking specific proteins vital for tumor growth, or stimulating the immune system to fight the disease. For example, in March 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, introduced IBYRA, a generic version of the PARP inhibitor olaparib, in India. This drug offers an affordable and targeted treatment option for patients with HRD-positive and BRCA-positive cancers, significantly reducing treatment costs compared to the innovator drug.

Who Are The Major Companies Operating In The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market?

Major companies operating in the poly(ADP-ribose) polymerase (PARP) inhibitors market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Merck & Co. Inc., Bayer AG, AstraZeneca plc, Bristol-Myers Squibb Company, GSK plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim, Vertex Pharmaceuticals Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., BeiGene LTD, Karyopharm Therapeutics Inc., Clovis Oncology Inc., Repare Therapeutics Inc., Ribon Therapeutics, Artios Pharma, IMPACT Therapeutics Inc., BiPar Sciences Inc., Allarity Therapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/polyadp-ribose-polymerase-parp-inhibitors-global-market-report

How Is Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Demand Varying Across Different Regions?

North America was the largest region in the poly(ADP-ribose) polymerase (PARP) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the poly(ADP-ribose) polymerase (PARP) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Report:

https://www.thebusinessresearchcompany.com/customise?id=22102&type=smp

Browse Through More Reports Similar to the Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market 2025, By The Business Research Company

Her2 Inhibitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/her2-inhibitor-global-market-report

Checkpoint Inhibitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-global-market-report

Protein Inhibitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/protein-inhibitor-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What is the Anticipated CAGR of the Polymyalgia Rheumatica Market, and What Factors Will Drive It?

In recent times, the market size for polymyalgia rheumatica has experienced a significant boost. The market, which is expected to be worth $1.28 billion in 2024, is estimated to swell to $1.36 billion by 2025, with a compound annual growth rate (CAGR) of 5.9%. The historical growth of this market is attributable to factors such as increased consciousness among medical care practitioners, the growing application of corticosteroids, the proliferation of specialty clinics, the advent of biological therapies, and the augmentation of healthcare budgets.

In the coming years, the polymyalgia rheumatica market is forecasted to experience robust growth. It is projected to reach $1.72 billion in 2029, with a compound annual growth rate (CAGR) of 6.1%. The predicted growth within this period can be ascribed to factors such as increased use of biologics, precision medicine advancements, expedited drug approvals, wider reimbursements, and growth of clinical trials. In the forecast period, key trends to watch include the emergence of combination therapies, improvements in personalized medicine, progress in precision medicine, the application of electronic health records, and the evolution of biomarkers.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22103&type=smp

Which Factors and External Forces Are Driving Demand in the Polymyalgia Rheumatica Market?

The surge in personalized medicine’s popularity is predicted to boost the polymyalgia rheumatica market’s growth. Personalized medicine, which tailors medical treatment to a person’s genetic profile, lifestyle, and specific health conditions for more effective results, is gaining traction due to advancements in genetic research, increasing patient expectations for individualized treatments, and enhancements in diagnostic technologies. Genetic research has given us a more comprehensive understanding of individual genetic variations, enabling more tailored treatments that target specific genetic markers. By choosing drugs based on a patient’s characteristics, personalized medicine can formulate a more effective and safer treatment plan. To illustrate, the Personalised Medicine Coalition, a U.S-based hospital, and healthcare organization reported in February 2024 that the Food and Drug Administration approved 16 new personalized treatments for rare diseases in 2023, a substantial increase from six in 2022. As a result, the surge in personalized medicine is a critical factor fuelling the polymyalgia rheumatica market’s growth.

Which Segments in the Polymyalgia Rheumatica Offer the Most Growth?

The polymyalgia rheumaticamarket covered in this report is segmented –

1) By Treatment: Corticosteroids; Nonsteroidal Anti-Inflammatory Drugs; Disease-Modifying Antirheumatic Drugs; Biologics

2) By Route Of Administration: Oral; Intravenous; Subcutaneous

3) By Patient Type: Adult; Geriatric; Periatric

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Subsegments:

1) By Corticosteroids: Prednisone; Methylprednisolone; Hydrocortisone; Dexamethasone

2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen; Naproxen; Aspirin; Celecoxib

3) By Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate; Leflunomide; Sulfasalazine; Hydroxychloroquine

4) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors; Interleukin-6 (IL-6) Inhibitors; B-Cell Inhibitors; Janus Kinase (JAK) Inhibitors

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=22103&type=smp

What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Polymyalgia Rheumatica Market?# Market?

Asia-Pacific was the largest region in the polymyalgia rheumatica market in 2024. The regions covered in the polymyalgia rheumatica market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Cutting-Edge Market Trends Are Expected to Drive thePolymyalgia Rheumatica Market’s Growth?

Leading entities in the polymyalgia rheumatica market, like Regeneron Pharmaceuticals, Inc., and Sanofi, are channeling efforts into creating more sophisticated drugs, such as interleukin-6 (IL-6) receptor blockers, to offer more targeted and efficient treatment alternatives. These blockers are biological drugs designed to restrain IL-6, a critical inflammatory agent in autoimmune diseases. As a result, these remedies reduce inflammation, enhance symptoms and improve the life quality for PMR patients. Notably, in February 2023, the U.S.-based biotechnology firm, Regeneron Pharmaceuticals, and the French healthcare firm, Sanofi, received approval from the Food and Drug Administration (FDA) for their drug, Kevzara (sarilumab), to treat PMR in adults who have insufficiently responded to corticosteroids or struggle to gradually stop their use. Kevzara, the singular approved biologic for this illness, operates by suppressing IL-6-induced signaling. This approval came after a clinical study demonstrated 28.3% of patients on sarilumab attained sustained remission by the 52nd week compared to 10.3% on a placebo. Kevzara is delivered bi-weekly through subcutaneous injection and has also been approved for treating moderately to severely active rheumatoid arthritis. Presently, the Sanofi stock (SNY) is valued at $54.13 on the NASDAQ.

View the full report here:

https://www.thebusinessresearchcompany.com/report/polymyalgia-rheumatica-global-market-report

What Are the Key Elements That Define the Polymyalgia Rheumatica Market?

Polymyalgia rheumatica (PMR) is an inflammatory disorder that primarily affects older adults, causing muscle pain and stiffness, particularly in the shoulders, hips, and neck. It is characterized by aching and swelling in the muscles around the shoulders and hips, leading to difficulty in movement and daily activities.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22103

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Key Milestones in the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market’s Growth Trajectory From 2025 To 2034?

The market for poly (adp-ribose) polymerase (parp) inhibitors has witnessed a considerable surge in recent years. There is a projected growth of the market size from $6.53 billion in 2024 to $7.49 billion in 2025, with a compound annual growth rate (CAGR) of 14.8%. The historic evolution can be credited to the climb in cancer cases, rise in genetic testing, greater success rates in clinical trials, increased insurance coverage, and progress in cancer research.

The market for poly (adp-ribose) polymerase (parp) inhibitors is anticipated to experience swift expansion in the upcoming years, expanding to a valuation of $13.15 billion in 2029, registering a compound annual growth rate (CAGR) of 15.1%. The predicted boom in this period owes its origin to an increase in the production and distribution of medications, the rising occurrence of BRCA-mutated cancers, an upward trend in breast cancer, increased utilization of monoclonal antibodies, and growing health expenditure. Predominant trends predicted for this period incorporate progress in biomarker research, combined treatment approaches, the utilization of artificial intelligence in drug creation, advancements in therapy based on biomarkers, and the evolution of next-generation PARP inhibitors.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22102&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market?

The growth of the poly(ADP-ribose) polymerase (PARP) inhibitors market is anticipated to be driven by the increasing incidence of breast cancer. Breast cancer is an illness characterized by uncontrolled cell growth in the breast, leading to a malignant tumor that can spread to other body parts. The escalating prevalence of breast cancer is linked to factors such as aging, lifestyle modifications, genetic predisposition, hormonal disorders, obesity, alcohol intake, and amplified exposure to environmental risks. PARP inhibitors aid in the treatment of breast cancer by inhibiting the PARP enzyme from repairing DNA damage in cancer cells, which results in cell death, particularly in tumors with BRCA1 or BRCA2 mutations. For example, the National Breast Cancer Foundation, located in the US, stated in January 2025 that one out of every eight women in the United States will be diagnosed with breast cancer in their lifetime. In 2024, cases of invasive breast cancer were reported in 310,720 women and 2,800 men. Consequently, the surge in breast cancer occurrences is promoting the expansion of the poly(ADP-ribose) polymerase (PARP) inhibitors market.

Which Key Market Segments Comprise the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market and Drive Its Revenue Growth?

The poly (adp-ribose) polymerase (parp) inhibitorsmarket covered in this report is segmented –

1) By Type: Olaparib; Rucaparib; Niraparib; Talazoparib; Other Types

2) By Indication: Ovarian Cancer; Breast Cancer; Prostate Cancer; Pancreatic Cancer

3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

4) By End-User: Hospitals; Specialty Clinics; Research Institutions; Other End-Users

Subsegments:

1) By Olaparib: BRCA-Mutated Cancers; HRD-Positive Cancers; Maintenance Therapy

2) By Rucaparib: Ovarian Cancer; Prostate Cancer; Pancreatic Cancer

3) By Niraparib: First-Line Treatment; Recurrent Cancer Treatment; Late-Stage Cancer

4) By Talazoparib: Breast Cancer; Germline BRCA-Mutated Tumors; Neoadjuvant Or Adjuvant Therapy

5) By Other Types: Emerging PARP Inhibitors; Investigational Therapies; Novel Combinations

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=22102&type=smp

Which Areas Are Leading Regions in the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Expansion Across the Globe?

North America was the largest region in the poly(ADP-ribose) polymerase (PARP) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the poly(ADP-ribose) polymerase (PARP) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in thePoly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Over the Coming Years?

Key players in the poly(ADP-ribose) polymerase (PARP) inhibitors market are honing in on crafting sophisticated cancer therapies, such as anticancer drugs, specifically aimed at characteristic genetic mutations seen in certain types of cancer. Anticancer drugs are employed to manage cancer by halting the proliferation of cancer cells, preventing their spread, or ultimately eliminating them. They function through several mechanisms of action, including interrupting cell division, hindering specific proteins that are crucial for tumor growth, or activating the immune system to combat the disease. For instance, in March 2024, India-based pharmaceutical tycoon, Zydus Lifesciences Limited, unveiled IBYRA, a generic counterpart of the PARP inhibitor olaparib, in India. This medication represents an economic and pinpointed treatment choice for patients suffering from HRD-positive and BRCA-positive malignancies. It substantially trims down treatment expenses when compared to the original drug.

View the full report here:

https://www.thebusinessresearchcompany.com/report/polyadp-ribose-polymerase-parp-inhibitors-global-market-report

How Is the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Conceptually Defined?

PARP inhibitors (poly(ADP-ribose) polymerase inhibitors) are a group of drugs mainly used in cancer therapy. These medications work by blocking DNA repair in cancer cells, particularly in cancers with BRCA mutations. They are commonly used to treat ovarian and breast cancer and are usually taken orally. PARP inhibitors help reduce the risk of cancer returning after chemotherapy and can cause side effects such as fatigue and low blood cell counts.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22102

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Polymyalgia Rheumatica Market Growth in 2025?

The market size for polymyalgia rheumatica has experienced considerable growth in the past few years. It’s expected to expand from $1.28 billion in 2024 to $1.36 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.6%. Factors contributing to this historic growth trend include heightened awareness among healthcare providers, increased usage of corticosteroids, the rise of specialty clinics, the advent of biologic therapies, and an increase in healthcare budgets.

What Is the Forecast for the Polymyalgia Rheumatica Market Size Through 2029?

The market size for polymyalgia rheumatica is projected to witness significant expansion in the coming years, increasing to $1.73 billion by 2029, with a compound annual growth rate (CAGR) of 6.2%. The anticipated growth during the forecast period can be attributed to factors such as the wider acceptance of biologics, the advancement of precision medicine, expedited drug approvals, extensive reimbursements, and an increase in clinical trials. Noteworthy trends expected during this forecast period include the progression in combination therapies, the groundbreaking advancements in personalized medicine, breakthroughs in precision medicine, the incorporation of electronic health records, and significant leaps in biomarkers.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22103&type=smp

What are the Key Market Players in Polymyalgia Rheumatica Market and How They’re Evolving?

Major companies operating in the polymyalgia rheumatica market are AbbVie Inc., Sanofi S.A., Eli Lilly and Co., Regeneron Pharmaceuticals Inc., Mount Sinai, NYU Langone Health, Mayo Foundation for Medical Education and Research, Hartford HealthCare, Horizon Therapeutics plc, Massachusetts General Hospital, Brigham and Women’s Hospital, Stanford Health Care, University Hospitals Bristol NHS Foundation Trust, Circle Health Group Ltd., Siloam Hospital, UC San Diego Health, Vejthani Hospital, Sparrow Pharmaceuticals Inc., Johns Hopkins Arthritis Center, Upstate University Hospital

What Are the Primary Growth Drivers in the Polymyalgia Rheumatica Market?

The increasing popularity of personalized medicine is anticipated to boost the polymyalgia rheumatica market’s expansion. Personalized medicine, which is adjusted to an individual’s genetic makeup, lifestyle, and specific health conditions for more effective results, drives this demand. The rise in personalized medicine is powered by developments in genetic research, increasing patient expectations for individualized treatments, and advancements in diagnostic technologies. A wealth of insights into individual genetic variations have been provided by genetic research, ushering in a new era of treatments targeted towards specific genetic markers. Personalized medicine aids in choosing the most likely effective drugs based on a patient’s characteristics, resulting in a more effective and safer treatment strategy. As per the Personalised Medicine Coalition, for example, in February 2024, a US healthcare organization revealed, the Food and Drug Administration had approved 16 novel personalized treatments for rare diseases in 2023, a significant increase from just six in 2022. Hence, the upsurge of personalized medicine is spurring the growth of the polymyalgia rheumatica market. The surge in telemedicine services due to increased convenience and remote care is fuelling the expansion of the polymyalgia rheumatica market. Using digital communication mediums like video calls, phone calls, and online messaging, telemedicine services render remote consultations, diagnoses, treatments, and follow-up care, eliminating the need for patients to physically visit healthcare facilities. The unprecedented growth in telemedicine services is owed to the rising demand for convenient and cost-effective healthcare solutions. Telemedicine caters to the popular demand for convenience, especially for non-emergency consultations, by removing the need for physical visits. The rise in telemedicine services assists polymyalgia rheumatica (PMR) by facilitating symptoms’ remote surveillance, medication management, and regular follow-ups, all essential for managing chronic pain and inflammation. For example, in November 2024, according to the Australian Bureau of Statistics, a government agency based in Australia, telehealth consultation usage rose from 87.7% in 2022-23 to 89.2% in 2023-24. As a result, the expansion of telemedicine services is catalysing the growth of the polymyalgia rheumatica market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=22103&type=smp

What Are the Leading Segments in the Global Polymyalgia Rheumatica Industry?

The polymyalgia rheumatica market covered in this report is segmented –

1) By Treatment: Corticosteroids, Nonsteroidal Anti-Inflammatory Drugs, Disease-Modifying Antirheumatic Drugs, Biologics

2) By Route Of Administration: Oral, Intravenous, Subcutaneous

3) By Patient Type: Adult, Geriatric, Periatric

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Corticosteroids: Prednisone, Methylprednisolone, Hydrocortisone, Dexamethasone

2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Naproxen, Aspirin, Celecoxib

3) By Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine

4) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin-6 (IL-6) Inhibitors, B-Cell Inhibitors, Janus Kinase (JAK) Inhibitors

What Are the Key Market Trends in the Polymyalgia Rheumatica Industry?

Leading companies in the polymyalgia rheumatica market are making strides in the production of advanced medications like interleukin-6 (IL-6) receptor blockers, aimed at offering more specific and impactful treatment choices. IL-6 receptor blockers, which are bio-drugs that suppress IL-6, an important inflammatory factor in autoimmune conditions, work by inhibiting IL-6, which in turn alleviates inflammation and symptoms, thereby improving the standard of living for patients with PMR. In February 2023, Regeneron Pharmaceuticals Inc., an American biotech firm, and Sanofi, a French healthcare establishment, reported FDA approval for Kevzara (sarilumab) to treat adult PMR patients who have had inadequate reactions to corticosteroids or are unable to endure the tapering process. Kevzara, the first and sole biologic approved for this disease, operates by blocking IL-6 mediated signaling. This sanction was grounded on research that showed that 28.3% of patients treated with sarilumab attained consistent remission at the 52-week mark, in comparison to a 10.3% remission rate in placebo-administered patients. It is given via a subcutaneous injection on a bi-weekly basis and is also sanctioned for the treatment of moderately to severely active rheumatoid arthritis. Sanofi’s share value (SNY) on the NASDAQ currently stands at $54.13.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/polymyalgia-rheumatica-global-market-report

What Is the Regional Outlook for the Polymyalgia Rheumatica Market?

Asia-Pacific was the largest region in the polymyalgia rheumatica market in 2024. The regions covered in the polymyalgia rheumatica market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22103

This Report Delivers Insight On:

1. How big is the polymyalgia rheumatica market, and how is it changing globally?

2. Who are the major companies in the polymyalgia rheumatica market, and how are they performing?

3. What are the key opportunities and risks in the polymyalgia rheumatica market right now?

4. Which products or customer segments are growing the most in the polymyalgia rheumatica market?

5. What factors are helping or slowing down the growth of the polymyalgia rheumatica market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the polymyalgia rheumatica industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What is the Anticipated CAGR of the Polymyalgia Rheumatica Market, and What Factors Will Drive It?

In the past few years, the polymyalgia rheumatica market size has witnessed significant growth. The projection is that it will expand from $1.28 billion in 2024 to $1.36 billion in 2025 with a compound annual growth rate (CAGR) of 6.6%. Factors that contributed to this historical growth include heightened awareness among healthcare professionals, increased utilization of corticosteroids, proliferation of specialty clinics, the advent of biologic therapies, and boosted healthcare budgets.

Strong expansion is anticipated in the polymyalgia rheumatica market in the coming years, with predictions estimating its value will reach $1.73 billion in 2029, stemming from a compound annual growth rate (CAGR) of 6.2%. This predicted increases are mainly due to the increased use of biologics, the broadening of precision medicine, an acceleration in drug approvals, more comprehensive reimbursements, and an enlargement in clinical trials. During the forecast period, key trends are expected to be the creation of combination therapies, breakthroughs in personalized medicine, precision medicine development, the inclusion of electronic health records, as well as progress in biomarkers.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22103&type=smp

What External and Internal Drivers Are Contributing to the Growth of the Polymyalgia Rheumatica Market?

The ascension in demand for tailored medical treatment, known as personalized medicine, is anticipated to boost the expansion of the polymyalgia rheumatica market. This individual-oriented medicine approach, influenced by an individual’s unique genetic makeup, lifestyle, and personal health state, brings more effective results. This personalized medical revolution has been propelled by progressive genetic studies, rising patient desires for bespoke treatment plans, and technological improvements in diagnostics. Understanding individual genetic variations through genetic studies has allowed for the creation of customized treatments targeting specific genetic markers. This individualized approach to medicine aids in drug selection, based on patient’s unique characteristics for a safer and more effective treatment agenda. For instance, the Personalised Medicine Coalition, a health care organisation based in the US, reported that in February 2024, the Food and Drug Administration approved 16 new bespoke treatments for rare disease patients in 2023, as compared to six in 2022. This surge in personalized medicine subsequently maneuvering the growth of the polymyalgia rheumatica market. As the ascension in telemedicine services is anticipated to encourage the expansion of the polymyalgia rheumatica market. Telemedicine services utilize digital communicative technologies, such as video and phone calls and online chatting, to extend remote medical consultations, diagnoses, treatment, and patients’ post-treatment care without the requirement of physical appointments. This ascension in telemedicine services is a response to rising demand for convenient and economical healthcare solutions. Telemedicine eradicates the necessity for physical appointments, offering convenience particularly for non-urgent consultations. The growth of these remote healthcare services is beneficial for managing polymyalgia rheumatica (PMR) as it enables distant symptom tracking, medication supervision, and regular patient follow-ups, all essential for managing long-lasting pain and inflammation. For example, the Australian Bureau of Statistics, a governmental agency based in Australia, reported in November 2024 that the proportion of individuals using telehealth consultations rose from 87.7% in 2022-23 to 89.2% in 2023-24. The escalating use of telemedicine services subsequently contributes to the expansion of the polymyalgia rheumatica market.

What Segment Types Define the Polymyalgia Rheumatica Market Structure?

The polymyalgia rheumatica market covered in this report is segmented –

1) By Treatment: Corticosteroids, Nonsteroidal Anti-Inflammatory Drugs, Disease-Modifying Antirheumatic Drugs, Biologics

2) By Route Of Administration: Oral, Intravenous, Subcutaneous

3) By Patient Type: Adult, Geriatric, Periatric

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Corticosteroids: Prednisone, Methylprednisolone, Hydrocortisone, Dexamethasone

2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Naproxen, Aspirin, Celecoxib

3) By Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine

4) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin-6 (IL-6) Inhibitors, B-Cell Inhibitors, Janus Kinase (JAK) Inhibitors

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=22103&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Polymyalgia Rheumatica Market?

Asia-Pacific was the largest region in the polymyalgia rheumatica market in 2024. The regions covered in the polymyalgia rheumatica market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the Polymyalgia Rheumatica Market?

Notable companies navigating the polymyalgia rheumatica market are prioritizing the creation of advanced medicinal treatments, particularly interleukin-6 (IL-6) receptor blockers, which offer a more precise, effective mode of action. These biological therapeutics function by inhibiting IL-6, an integral pro-inflammatory cytokine in the context of autoimmune diseases. By obstructing IL-6, these interventions create a cascade of effects that decrease inflammation and ameliorate symptoms, improving life quality for those suffering from PMR. As an example, Regeneron Pharmaceuticals Inc., originating from the U.S., and Sanofi, a healthcare enterprise based in France, publicly stated in February 2023 that the FDA had approved their joint product, Kevzara (sarilumab), for the treatment of polymyalgia rheumatica in adults who are not optimally responsive to corticosteroids or who have trouble easing off them. Kevzara is singular in its status as the first and only biological agent approved for this condition, and it accomplishes its therapeutic goal by interfering with IL-6-mediated signaling. This approval was fueled by the results of a trial where 28.3% of patients under sarilumab obtained sustained remission by the 52nd week, as opposed to only the 10.3% who were given a placebo. The treatment protocol for Kevzara involves a subcutaneous injection every fortnight, and it carries an additional approval for the management of moderately to severely active rheumatoid arthritis. Sanofi’s shares (SNY) are presently valued at $54.13 on the NASDAQ market.

View the full report here:

https://www.thebusinessresearchcompany.com/report/polymyalgia-rheumatica-global-market-report

What Is the Definition of the Polymyalgia Rheumatica Market?

Polymyalgia rheumatica (PMR) is an inflammatory disorder that primarily affects older adults, causing muscle pain and stiffness, particularly in the shoulders, hips, and neck. It is characterized by aching and swelling in the muscles around the shoulders and hips, leading to difficulty in movement and daily activities.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22103

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model